ncp112
Peptideexperimental
Clinical trial activity
2 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Oct 13, 2021 (NCT05638165)
Timeline
2020s
- Jan 1, 2021
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Lipoxin A4 receptorACTIVATOR
FPR2 activator
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06263998 | Phase 1 | Jul 11, 2024 | Huons Co.,Ltd., Seoul National University |
| NCT05638165 | Phase 1 | Oct 13, 2021 | NovaCell Technology Inc. |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Huons Co.,Ltd. | For profit | 1 | 1 | 1 | 2024 |
| NovaCell Technology Inc. | For profit | 1 | 1 | 1 | 2021 |
| Seoul National University | Academic/Hospital | 1 | 0 | 1 | 2024 |
3 organizations
Page 1 / 1